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In a recent commentary, Gage and Munafó 1 argued that we should rethink the accepted role of 
cigarette smoking in schizophrenia:  as a form of self-medication 2.  They argue that evidence from 
recent genome-wide association studies 3, 4suggest that Mendelian randomisation analyses could be 
used test the hypothesis that cigarette smoking may play a causal role in schizophrenia. They also 
argue that the consistent association reported between cannabis use and schizophrenia in 
longitudinal studies 5 could also be explained by the hypothesis that cigarette smoking increases the 
likelihood of using cannabis and developing schizophrenia. 
 
Gage and Munafó do not fully address some important issues relating to linkages between cigarette 
smoking, cannabis use and psychosis. The first is the lack of neurophysiological pathways by which 
smoking could increase the risks of psychosis. A second issue is the lack of reports of tobacco or 
nicotine-induced psychoses or psychotic symptoms. This is in marked contrast to clinical reports and 
laboratory studies of cannabis-induced psychotic symptoms.  
 
Gage and Munafó argue that Mendelian randomisation  provides a unique method for addressing 
the control of non-observed confounding factors that are not addressed by conventional methods of 
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statistical adjustment 6.  However, Mendelian randomisation is not the only method for controlling 
non-observed sources of confounding.  As we have previously commented , there is an alternative 
approach for studying the associations between time-dynamic outcomes such as cannabis use, 
tobacco use and psychotic symptoms: fixed effects regression 7.  The fixed effects regression model 
makes it possible to control all non-observed sources of confounding (U), both genetic and 
environmental, that may be correlated with a time-varying exposure variable Xt and have fixed and 
enduring effects on a time dynamic outcome Zt. We have previously used this methodology to 
examine the associations between cannabis use and psychotic symptoms in a New Zealand birth 
cohort 7.  
 
We tested the hypotheses suggested by Gage and Munafó using repeated measures data collected 
at ages 18, 21, 25 , 30 and 35 during the course of the Christchurch Health and Development Study. 
We used these data to examine the associations between the frequency of cigarette smoking, the 
frequency of  cannabis use and rates of psychotic symptoms (measured by the SCL-908 at ages 18-25 
and the Diagnostic Interview Schedule 9 at ages 30-35). The fitted model included both cigarette 
smoking and cannabis use as fixed effects as well as a number of time dynamic covariates, including 
concurrent measures of: alcohol use disorder; major depression; anxiety disorder; life stress; and 
deviant peer affiliations.   The final model fitted was a negative binomial model in which the natural 
logarithm of the number of psychotic symptoms at each age Yt was modelled as a linear function of: 
a) cigarette smoking X1; b) cannabis use X2; c) non-observed fixed sources of confounding (U); d) 
time-varying covariates (Zt); and e) random error (Et).  This model was fitted to the data using Stata 
12.0 10.  The sample sizes ranged from 1025 (age 18) to 962 (age 35), representing 79% to 82% of the 
surviving sample at each assessment. 
 
Table 1 shows: a) the bivariate associations between tobacco use, cannabis use and psychotic 
symptoms pooled over the five observation periods; and b) the model parameters for tobacco and 
cannabis after adjustment for fixed effects and time-dynamic covariates. The Table shows that the 
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frequency of both tobacco and cannabis use were significantly (p<.0001) related to rates of 
psychotic symptoms.  After adjustment, cannabis use remained significantly related to rates of 
psychotic symptoms (B = .13; SE = .04; p <.001) whereas cigarette smoking  did not (B = .08; SE = 
.05;p >.10).  These findings suggest a possible causal effect of cannabis use on rates of psychotic 
symptoms, and imply that the associations between cigarette smoking and cannabis use are 
explained by the effects of: a) the associations between cigarette smoking and cannabis;  b) non-
observed fixed effects common to tobacco and cannabis; and c) time-dynamic covariates associated 
with cannabis use.   
 
INSERT TABLE 1 HERE 
 
These findings do not support the hypothesis that cigarette smoking plays a role in the development 
of psychotic symptoms. They do, however, support the hypothesis that cannabis use influences the 
risk of psychotic symptoms 5.  It is important to note that the outcome measure used in our study 
was not a measure of schizophrenia but rather a more general measure of psychotic symptoms. This 
difference could explain the differences between the findings of our study and the hypotheses 
advanced by Gage and Munafó.  Nonetheless the failure of our analysis to support the application of 
Mendelian randomisation to examine the linkages between smoking and schizophrenia studies 
suggests the need for more comprehensive analyses of data on tobacco smoking, cannabis and 
psychosis before we accept the premise that cigarette smoking may be a cause of psychosis and 
reject a causal role for cannabis use in psychosis. 
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Table 1   Associations between psychotic symptoms and frequency of: a) cannabis use; and b) 
cigarette smoking, ages 18-35, before and after controlling for non-observed fixed effects and 
time-dynamic covariate factors 
 Before adjustment  After adjustment1 
 B SE p  B SE p 
Frequency of cannabis use .28 .02 <.0001  .13 .04 <.001 
Frequency of cigarette smoking .30 .03 <.0001  .08 .05 >.10 
1 Statistically significant (p < .05) time-dynamic covariate factors included:  major depression; 
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